Andrew J. Perlman - Jun 14, 2022 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Role
Director
Signature
/s/ Carolyn Tang, Attorney-in-Fact
Stock symbol
RCUS
Transactions as of
Jun 14, 2022
Transactions value $
$0
Form type
4
Date filed
6/16/2022, 04:34 PM
Previous filing
Jun 7, 2021
Next filing
Jun 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCUS Common Stock Award $0 +4.1K +58.36% $0.00 11.1K Jun 14, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RCUS Stock Option (Right to Buy) Award $0 +16.8K $0.00 16.8K Jun 14, 2022 Common Stock 16.8K $20.62 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of restricted stock units that vest in full on the earlier of June 14, 2023 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.
F2 Includes 1,500 and 3,000 shares of restricted stock units (previously reported) that vested on December 15, 2021 and June 3, 2022, respectively.
F3 The option will vest in full on the earlier of June 14, 2023 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.